Theranexus Reports €2.12M Cash Reserves as of June 30, 2025, Amid Strategic Cost-Cutting
- How Did Theranexus Reduce Its Operating Costs?
- What’s Driving Theranexus’ Financial Performance?
- What’s Next for Theranexus?
- FAQs: Theranexus’ H1 2025 Financials
Theranexus, a pioneering biopharmaceutical firm specializing in rare neurological diseases, has released its half-year financial results for 2025. The company’s cash reserves surged to €2.12 million, up from €967K in 2024, while operational costs dropped by 20% YoY. Key priorities include advancing TX01 with partner Exeltis and Batten-1, backed by promising clinical data. Here’s a DEEP dive into their financial health and strategic moves.
How Did Theranexus Reduce Its Operating Costs?
Theranexus slashed operating expenses by nearly 20% in H1 2025 compared to H1 2024, building on a 41% cut the previous year. External purchases and R&D costs fell to €1.04M (from €1.29M), while payroll expenses dropped to €855K (from €1.07M). Staff reductions—from 12 to 10 employees—played a role. "We’ve tightened spending without compromising our pipeline," noted CEO Mathieu Charvériat. The company also benefited from €817K in grants, including non-repayable advances from BPI France.
What’s Driving Theranexus’ Financial Performance?
Despite a €1.07M semestrial loss (vs. a €101K profit in 2024), Theranexus’ liquidity improved sharply. Grants and a €37K research tax credit offset some costs. The end of Batten-1’s Phase 1/2 trial in 2024 reduced clinical study expenses, while broader cost-saving measures took hold. "Our focus is on delivering TX01 to market by 2028," Charvériat emphasized.
What’s Next for Theranexus?
Investors should watch for the September 30, 2025, treasury update on October 23. The firm continues exploring partnerships to accelerate Batten-1 and TX01 development. With €2.12M in cash, Theranexus has runway to advance its dual priorities—but the road to 2028 approvals remains long.
FAQs: Theranexus’ H1 2025 Financials
How much cash does Theranexus have as of June 2025?
€2.12 million, up from €967K in June 2024.
Why did Theranexus post a loss despite cost cuts?
Lower grants and higher R&D focus led to a €1.07M deficit, though liquidity improved.
When is the next financial update?
October 23, 2025, covering treasury data through September 30.
